Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.61 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.61 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9436142 | 1.00 | TDP1 (0.61) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11063940 | 1.00 | TDP1 (0.61) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL7040792 | 1.00 | TDP1 (0.61) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL7030196 | 1.00 | TDP1 (0.61) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL14065430 | 0.94 | TDP1 (0.62) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11674593 | 0.94 | TDP1 (0.62) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11674589 | 0.94 | TDP1 (0.62) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11796727 | 0.92 | TDP1 (0.60) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11688218 | 0.92 | TDP1 (0.60) | TDP1MAPTHPGDNR1I2CTDSP1 | |
| SCHEMBL11585087 | 0.92 | TDP1 (0.60) | TDP1MAPTHPGDNR1I2CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280808-A1 | IMPROVED BETA-LACTAM ANTIBIOTICS | NewBiotics, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020115642-A1 | 3-(2-(2,4-dichlorophenoxy)-5-chlorophenoxy)methyl-7-(2 -thienylacetamido)-3-cephem-4-carboxylic acid; for antibiotic (vancomycin) sensitive/resistant microorganisms | NEWBIOTICS, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2001083492-A1 | IMPROVED BETA-LACTAM ANTIBIOTICS | NEWBIOTICS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-0484966-B1 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | EISAI CO LTD (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1074554-A2 | 7-acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1074553-A1 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-5741902-A | INTERMEDIATES FOR CEPHEM ANTIBACTERIAL COMPOUNDS | EISAI CO., LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0761671-A1 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5604217-A | CEPHALOSPORIN ANTIBIOTICS | EISAI CO., LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| US-5587473-A | BLOCKING; CONDENSATION; DEBLOCKING | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5563265-A | BACTERICIDES | EISAI CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5559225-A | ANTIBIOTICS | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0484966-A2 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-5017569-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1991-05-21 | — | — | US | disclosed |
| EP-0267733-A2 | Cephalosporin compounds, process for their preparation and pharmaceutical compositions containing them | ZENECA Pharma S.A. (FR) | 1988-05-18 | — | — | EP | disclosed |
| US-3950329-A | FLUORINATED CEPHALOSPORINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115642-A1 | 3-(2-(2,4-dichlorophenoxy)-5-chlorophenoxy)methyl-7-(2 -thienylacetamido)-3-cephem-4-carboxylic acid; for antibiotic (vancomycin) sensitive/resistant microorganisms | DAO, APEH, HGF | TDP1 4410/4885MAPT 3360/4885HPGD 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.